

PCT/EP 00 / 06917

ET/6917 10/031509

EPO - DG 1

17. 07. 2000

(55)

PA 268094

# THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

REC'D 17 AUG 2000

WIPO PCT

June 28, 2000

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE UNDER 35 USC 111.

APPLICATION NUMBER: 60/144,106

FILING DATE: July 16, 1999

## PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)



By Authority of the  
COMMISSIONER OF PATENTS AND TRADEMARKS

*N. Woodson*  
N. WOODSON  
Certifying Officer

07/16/99  
10000 U.S. PTO

Please type a plus sign (+) inside the



Approved for use through 01/31/99. OMB 0651-0037  
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53 (c).

INVENTOR(S)					
Given Name (first and middle [if any])		Family Name or Surname		Residence (City and either State or Foreign Country)	
Marion		de Jong		The Netherlands	
<input type="checkbox"/> Additional inventors are being named on the ___ separately numbered sheets attached hereto					
TITLE OF THE INVENTION (280 characters max)					
COMBINATION OF LYSINE AND ARGININE FOR REDUCTION OF KIDNEY UPTAKE OF PHARMACEUTICALS					
CORRESPONDENCE ADDRESS					
Direct all correspondence to:					
<input type="checkbox"/> Customer Number				Place Customer Number Bar Code Label here	
OR					
<input checked="" type="checkbox"/> Firm or Individual Name		Mallinckrodt Inc.			
Address		675 McDonnell Blvd.			
Address		P.O. Box 5840			
City		St. Louis		State	MO
Country		USA		ZIP	63134
		Telephone		314 654-8955	Fax 314 654-3156
ENCLOSED APPLICATION PARTS (check all that apply)					
<input checked="" type="checkbox"/> Specification Number of Pages		1		<input type="checkbox"/> Small Entity Statement	
<input type="checkbox"/> Drawing(s) Number of Sheets				<input type="checkbox"/> Other (specify)	
METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT (check one)					
<input type="checkbox"/> A check or money order is enclosed to cover the filing fees				FILING FEE AMOUNT (\$)	
<input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number				131160	
				\$150	
The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.					
<input type="checkbox"/> No.					
<input type="checkbox"/> Yes, the name of the U.S. Government agency and the Government contract number are:					

Respectfully submitted

SIGNATURE

*Jeffrey S. Boone*

TYPED or PRINTED NAME

Jeffrey S. Boone

TELEPHONE

314 654-8955

Date

7/16/99

REGISTRATION NO.

(if appropriate)

Docket Number:

29,284

1406 P

## USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT

This collection of information is required by 37 CFR 1.51. The information is used by the public to file (and by the PTO to process) a provisional application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 8 hours to complete, including gathering, preparing, and submitting the complete provisional application to the PTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C., 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Box Provisional Application, Assistant Commissioner for Patents, Washington, D.C., 20231.

A/PROV

10000 U.S. PTO

60/144106

07/16/99

50144106-071699

1. Title of the invention : Combination of lysine and arginine for reduction of kidney reuptake of pharmaceuticals.
2. Brief Description of the Invention : Radio(metal)labeled peptides (and also monoclonal fragments and other compounds like certain antibiotics) undergo undesired renal reuptake and cellular retention, leading to a high kidney dose. Reduction of this re-uptake is possible using positively charged amino acids, L- and D-lysine being twice more effective than L-arginine in rat studies. In humans L-lysine was effective but at high doses it caused hyperkalemia in a number of patients. We found that the combination of L-lysine and L-arginine is significantly more effective at equimolar concentrations in reduction of kidney reuptake than both compounds alone.
3. Purpose of the Invention : To reduce kidney uptake of radiolabeled pharmaceuticals with such low doses of the combination of lysine and arginine (either in the L- or D-form) that the desired reduction of kidney uptake is achieved but hyperkalemia is prevented.
4. Detailed Description of the Invention : Radio(metal)labeled peptides (and also monoclonal fragments) undergo significant renal reuptake and cellular retention reducing the detection sensitivity of perirenal tumors and increasing kidney radiotoxicity during radionuclide therapy. We could reduce reuptake of the radiocompounds in the rat kidney in vivo: the most pronounced effects (50% inhibition of total kidney uptake) were obtained by D- and L-lysine (max effect achieved using 400 mg/kg). L-arginine gave a reduction of 20-30% at an equimolar dose. In human studies 15, 21 and 40% reduction of kidney uptake of [<sup>111</sup>In-DTPA]octreotide was reached using a dose of 25, 50 and 75 g L-lysine, respectively. The doses of 25 and 50 g L-lysine were well tolerated without any toxicity noted. However, the 75 g L-lysine dose was associated with hyperkalemia in 60% of the patients, which may result in cardiotoxicity.
5. We have found that the combination of L-lysine and L-argine is more effective for reduction of kidney reuptake in rats than both compounds alone at equimolar concentrations. Using this combination, lower doses of the two amino acids can therefore effectively inhibit the (radio)pharmaceutical kidney reuptake and prevent hyperkalemia and cardiotoxicity.
6. Known References: 1) De Jong M, Rolleman EJ, Bernard BF, Visser TJ, Breeman WAP, Krenning EP. Inhibition of renal uptake of Indium-111-octreotide in vivo. J Nucl Med 37(8):1388-1392, 1996. 2) Bernard HF, Krenning EP, Breeman WAP, Rolleman EJ, Bakker WH, Visser TJ, Mäcke HR, De Jong M. D-lysine reduction of <sup>111</sup>In Octreotide and <sup>90</sup>Y Octreotide renal uptake. J Nucl Med 38:1929-1933, 1997.

**THIS PAGE BLANK (USPTO)**